An early detection diagnostic test designed for clinical practice to identify Alzheimer's disease at preliminary stages. The test utilizes proprietary technology to support early diagnosis and patient management in clinical settings.
Manufactured by
Sant Feliu de Llobregat (Barcelona), Spain
ADmit Therapeutics, S.L. is a company that has developed the MAP-AD® Test for the early detection of Alzheimers dementia and is currently in the commercialization stage. Alzheimers Disease (AD) is a devastating process for patients and their families and a threat to public health systems in both developed and emerging countries. It is an unmet medical need. It is estimated that more than 47 million people worldwide are suffering this disease, and that the incidence will increase considerably in the coming years due to the increase in life expectancy (130 million patients in 2050). Currently, there is an infradiagnosis of AD cases (mostly in the mild stage), and it is usually done in the moderate stage and with a delay of 12-24 months after the onset of symptoms. There is no any IVD implemented in clinical practice to predict progression to Alzheimers dementia in patients with Mild Cognitive Impairment. Our IVD represents the determination of a number of biomarkers not related to either β-amyloid or tau in a blood sample. Our value proposition is based on an epigenetic analysis covering a large number of methylcytosines using next-generation sequencing techniques. Our proprietary biomarkers combined with the age, the ApoE genotype and the CDR-SOB represent a very useful tool for the prognosis of progression to Alzheimers dementia in Mild Cognitive Impairment patients. This cutting-edge technology provides a comprehensive analysis of the patient.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
BioChain (Beijing) Science & Technology. Inc.
China · 4 relevant products
Lansion Biotechnology Co., Ltd.
China · 2 relevant products
Fujirebio Diagnostics,Inc.
China · 7 relevant products
Weihai Kangzhou Biotechnology Engineering Co.,Ltd
China · 4 relevant products
Glycanostics, s.r.o.
Slovakia · 1 relevant product
Origin Biotechnology Co., Ltd.
Taiwan · 1 relevant product
SHENZHEN ANQUN BIOTECH CO.,LTD.
China · 9 relevant products
Anhui Huibang Biological Engineering Co., Ltd.
China · 3 relevant products
Lumigenex (Suzhou) Co., Ltd
China · 2 relevant products
Biomerica, Inc.
United States · 4 relevant products
49 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →4 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 99 closest product alternatives
BioChain (Beijing) Science & Technology. Inc. · China
Diagnostic test for early detection of cognitive impairment and neurodegenerative disease risk. This biomarker-based test supports early intervention strategies for age-related cognitive disorders. The product aligns with research collaborations in epigenetic disease markers.
Lansion Biotechnology Co., Ltd. · China
Dry fluorescence immunoassay test kit for Alzheimer disease-associated protein detection. Enables rapid neurodegenerative disease screening.
BioChain (Beijing) Science & Technology. Inc. · China
Biomarker-based diagnostic test for early detection and screening of diabetes mellitus. This test supports the company's focus on early identification and intervention in metabolic diseases. The product is part of comprehensive chronic disease screening offerings.
Fujirebio Diagnostics,Inc. · China
A cerebrospinal fluid detection test for Alzheimer's disease core biomarkers that provides enhanced sensitivity and more accurate results. This product targets the pathological hallmarks of Alzheimer's disease.
BioChain (Beijing) Science & Technology. Inc. · China
Epigenetic-based diagnostic test for early detection of cerebrovascular disease and stroke risk. Developed in collaboration with Beijing Tiantan Hospital, this test supports stroke prevention initiatives. The product integrates findings from a large-scale stroke cohort study.
Weihai Kangzhou Biotechnology Engineering Co.,Ltd · China
A diagnostic test for detecting drug abuse. The product is part of the company's clinical diagnostic testing services.
BioChain (Beijing) Science & Technology. Inc. · China
Advanced early detection test for lung cancer screening utilizing molecular diagnostic technology. This in-development product represents the company's expansion into early detection for pulmonary malignancies. The test is designed for high-risk population screening and clinical intervention.
Glycanostics, s.r.o. · Slovakia
Early-stage prostate cancer diagnostic test utilizing advanced glycan analysis for highly accurate detection. Designed to identify prostate cancer at initial stages, enabling timely clinical intervention and improved patient outcomes.
Origin Biotechnology Co., Ltd. · Taiwan
A diagnostic test for the assessment and diagnosis of dementia in elderly patients using molecular biomarkers.
Weihai Kangzhou Biotechnology Engineering Co.,Ltd · China
A diagnostic test for detecting various diseases. The product is included in the company's clinical diagnostic testing offerings.
SHENZHEN ANQUN BIOTECH CO.,LTD. · China
Enzyme-linked immunoassay (ELISA) kit for quantitative detection of human beta amyloid 1-42 in serum or plasma samples. Designed for early diagnosis and assessment of Alzheimer's disease and neurodegenerative disorders. The kit provides reliable biomarker measurement to support clinical evaluation of cognitive decline and dementia risk.
Lansion Biotechnology Co., Ltd. · China
Dry fluorescence immunoassay test kit for amyloid-beta protein detection. Supports assessment of Alzheimer disease pathology.
87 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products